The technology can be applied to guide decision making in drug discovery, characterize responder and nonresponder populations in clinical trials, and detect/evaluate drug-related adverse events, risk factors, and at-risk populations. KEM can also be applied to identify predictive biomarkers of clinical adverse events, safety and efficacy, and biomarkers for potential applications in prognostic and companion diagnostic assays.

Ariana has provided its KEM Biomarker technology to FDA since 2010 to help agency reviewers analyze pharmacogenomic data in combination with patient characteristics for biomarker signatures submitted through the FDA’s Voluntary Exploratory Data Submission (VXDS) program. The firm also has a collaboration with Bio-Rad France and AP-HP (Beaujon Hospital) and INSERM’s joint center of excellence for viral hepatitis focused on applying the KEM technology to the discovery of biomarkers for the early diagnosis of fibrosis and prediction of treatment resistance.

Headquartered in Paris, France, Ariana established a permanent base in Cambridge, MA earlier this year to support its client base in the U.S.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.